BACKGROUND: Little is known about the association of atrial fibrillation symptom burden with quality of life and outcomes. METHODS AND RESULTS: In the Prevention of Thromboembolic Events-European Registry in Atrial Fibrillation (n=6196 patients with atrial fibrillation; mean±SD age, 71.8±10.4 years; 39.7% women), we assessed European Heart Rhythm Association score symptoms and calculated correlations with the standardized health status questionnaire (EQ-5D-5L). Patients were followed up for atrial fibrillation therapies and outcomes (stroke/transient ischemic attack/arterial thromboembolism, coronary events, heart failure, and major bleeding) over 1 year. Most individuals (92%) experienced symptoms. Correlations with health status and quality of life were modest. In multivariable-adjusted regression models, the dichotomized European Heart Rhythm Association score (intermediate/frequent versus never/occasional symptoms) was associated with cardioversions (odds ratio [OR], 1.21; 95% confidence interval [CI], 1.01-1.45) and catheter ablation (OR, 1.97; 95% CI, 1.44-2.69), and inversely related with heart rate control (OR, 0.80; 95% CI, 0.70-0.92) and heart failure incidence (OR, 1.65; 95% CI, 1.16-2.34). Anxiety was inversely related with stroke/transient ischemic attack/arterial thromboembolism (OR, 0.55; 95% CI, 0.32-0.93), whereas chest pain related positively with coronary events (OR, 2.45; 95% CI, 1.42-4.22). Fatigue (OR, 1.84; 95% CI, 1.30-2.60), dyspnea (OR, 2.33; 95% CI, 1.63-3.33), and anxiety (OR, 1.72; 95% CI, 1.16-2.55) were associated with heart failure incidence. Palpitations were positively associated with cardioversion (OR, 1.32; 95% CI, 1.08-1.61) and ablation therapy (OR, 2.02; 95% CI, 1.48-2.76). CONCLUSIONS: A higher symptom burden, in particular palpitations, predicted interventions to restore sinus rhythm. The score itself had limited predictive value, but its individual components were related to different and specific clinical events, and may thus be helpful to target patient management.

Daiichi Sankyo Europe Munich Germany

Fondazione G Monasterio Pisa Italy

G d'Annunzio University Chieti Italy

German Center for Cardiovascular Research partner site Hamburg Kiel Lübeck Germany

Institute of Cardiovascular Sciences University of Birmingham United Kingdom

Medical Faculty Pilsen of Charles University Prague Czech Republic

Sandwell and West Birmingham Hospitals NHS Trust Birmingham United Kingdom

University Heart Center Hamburg Eppendorf Hamburg Germany

Zobrazit více v PubMed

Chugh SS, Havmoeller R, Narayanan K, Singh D, Rienstra M, Benjamin EJ, Gillum RF, Kim YH, McAnulty JH Jr, Zheng ZJ, Forouzanfar MH, Naghavi M, Mensah GA, Ezzati M, Murray CJ. Worldwide epidemiology of atrial fibrillation: a Global Burden of Disease 2010 Study. Circulation. 2014;129:837–847. PubMed PMC

Wyse DG. Overview of endpoints in atrial fibrillation studies. Heart Rhythm. 2004;1(suppl):B3–B7, discussion B7. PubMed

Kirchhof P, Auricchio A, Bax J, Crijns H, Camm J, Diener H‐C, Goette A, Hindricks G, Hohnloser S, Kappenberger L, Kuck K‐H, Lip GYH, Olsson B, Meinertz T, Priori S, Ravens U, Steinbeck G, Svernhage E, Tijssen J, Vincent A, Breithardt G. Outcome parameters for trials in atrial fibrillation: recommendations from a consensus conference organized by the German Atrial Fibrillation Competence NETwork and the European Heart Rhythm Association. Europace. 2007;9:1006–1023. PubMed

Wynn GJ, Todd DM, Webber M, Bonnett L, McShane J, Kirchhof P, Gupta D. The European Heart Rhythm Association symptom classification for atrial fibrillation: validation and improvement through a simple modification. Europace. 2014;16:965–972. PubMed PMC

Boriani G, Laroche C, Diemberger I, Fantecchi E, Popescu MI, Rasmussen LH, Sinagra G, Petrescu L, Tavazzi L, Maggioni AP, Lip GYH. Asymptomatic atrial fibrillation: clinical correlates, management, and outcomes in the EORP‐AF Pilot General Registry. Am J Med. 2015;128:509–518.e502. PubMed

Freeman JV, Simon DN, Go AS, Spertus J, Fonarow GC, Gersh BJ, Hylek EM, Kowey PR, Mahaffey KW, Thomas LE, Chang P, Peterson ED, Piccini JP. Association between atrial fibrillation symptoms, quality of life, and patient outcomes: results from the outcomes registry for better informed treatment of atrial fibrillation (ORBIT‐AF). Circ Cardiovasc Qual Outcomes. 2015;8:393–402. PubMed

Kirchhof P, Ammentorp B, Darius H, De Caterina R, Le Heuzey J‐Y, Schilling RJ, Schmitt J, Zamorano JL. Management of atrial fibrillation in seven European countries after the publication of the 2010 ESC guidelines on atrial fibrillation: primary results of the PREvention oF thromboemolic events—European Registry in Atrial Fibrillation (PREFER in AF). Europace. 2014;16:6–14. PubMed PMC

Janssen MF, Pickard AS, Golicki D, Gudex C, Niewada M, Scalone L, Swinburn P, Busschbach J. Measurement properties of the EQ‐5D‐5L compared to the EQ‐5D‐3L across eight patient groups: a multi‐country study. Qual Life Res. 2013;22:1717–1727. PubMed PMC

Prins M, Guillemin I, Gilet H, Gabriel S, Essers B, Raskob G, Kahn S. Scoring and psychometric validation of the Perception of Anticoagulant Treatment Questionnaire (PACT‐Q©). Health Qual Life Outcomes. 2009;7:30. PubMed PMC

Rabin R, de Charro F. EQ‐5D: a measure of health status from the EuroQol Group. Ann Med. 2001;33:337–343. PubMed

Kirchhof P, Benussi S, Kotecha D, Ahlsson A, Atar D, Casadei B, Castella M, Diener HC, Heidbuchel H, Hendriks J, Hindricks G, Manolis AS, Oldgren J, Popescu BA, Schotten U, Van Putte B, Vardas P, Agewall S, Camm J, Baron Esquivias G, Budts W, Carerj S, Casselman F, Coca A, De Caterina R, Deftereos S, Dobrev D, Ferro JM, Filippatos G, Fitzsimons D, Gorenek B, Guenoun M, Hohnloser SH, Kolh P, Lip GY, Manolis A, McMurray J, Ponikowski P, Rosenhek R, Ruschitzka F, Savelieva I, Sharma S, Suwalski P, Tamargo JL, Taylor CJ, Van Gelder IC, Voors AA, Windecker S, Zamorano JL, Zeppenfeld K. 2016 ESC guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Europace. 2016;18:1609–1678. PubMed

Kuck KH, Furnkranz A, Chun KR, Metzner A, Ouyang F, Schluter M, Elvan A, Lim HW, Kueffer FJ, Arentz T, Albenque JP, Tondo C, Kuhne M, Sticherling C, Brugada J. Cryoballoon or radiofrequency ablation for symptomatic paroxysmal atrial fibrillation: reintervention, rehospitalization, and quality‐of‐life outcomes in the FIRE AND ICE trial. Eur Heart J. 2016;37:2858–2865. PubMed PMC

Woźniak‐Skowerska IM, Skowerski MJ, Hoffmann A, Nowak S, Faryan M, Kolasa J, Skowerski T, Szydło K, Wnuk‐Wojnar AM, Mizia‐Stec K. Quality of life in patients with paroxysmal atrial fibrillation after circumferential pulmonary vein ablation. Kardiol Pol. 2016;74:244–250. PubMed

Nikolaidou T, Channer KS. Chronic atrial fibrillation: a systematic review of medical heart rate control management. Postgrad Med J. 2009;85:303–312. PubMed

Reynolds MR, Lavelle T, Essebag V, Cohen DJ, Zimetbaum P. Influence of age, sex, and atrial fibrillation recurrence on quality of life outcomes in a population of patients with new‐onset atrial fibrillation: the Fibrillation Registry Assessing Costs, Therapies, Adverse events and Lifestyle (FRACTAL) study. Am Heart J. 2006;152:1097–1103. PubMed PMC

Flaker GC, Belew K, Beckman K, Vidaillet H, Kron J, Safford R, Mickel M, Barrell P. Asymptomatic atrial fibrillation: demographic features and prognostic information from the Atrial Fibrillation Follow‐up Investigation of Rhythm Management (AFFIRM) study. Am Heart J. 2005;149:657–663. PubMed

Healey JS, Connolly SJ, Gold MR, Israel CW, Van Gelder IC, Capucci A, Lau CP, Fain E, Yang S, Bailleul C, Morillo CA, Carlson M, Themeles E, Kaufman ES, Hohnloser SH. Subclinical atrial fibrillation and the risk of stroke. N Engl J Med. 2012;366:120–129. PubMed

Rienstra M, Vermond RA, Crijns HJGM, Tijssen JGP, Van Gelder IC. Asymptomatic persistent atrial fibrillation and outcome: results of the RACE study. Heart Rhythm. 2014;11:939–945. PubMed

Vermond RA, Crijns HJGM, Tijssen JGP, Alings AM, Van den Berg MP, Hillege HL, Van Veldhuisen DJ, Van Gelder IC, Rienstra M. Symptom severity is associated with cardiovascular outcome in patients with permanent atrial fibrillation in the RACE II study. Europace. 2014;16:1417–1425. PubMed

Emdin CA, Odutayo A, Wong CX, Tran J, Hsiao AJ, Hunn BH. Meta‐analysis of anxiety as a risk factor for cardiovascular disease. Am J Cardiol. 2016;118:511–519. PubMed

Boriani G, Laroche C, Diemberger I, Fantecchi E, Popescu MI, Rasmussen LH, Dan GA, Kalarus Z, Tavazzi L, Maggioni AP, Lip GY. “Real‐world” management and outcomes of patients with paroxysmal vs. non‐paroxysmal atrial fibrillation in Europe: the EURObservational Research Programme‐Atrial Fibrillation (EORP‐AF) General Pilot Registry. Europace. 2016;18:648–657. PubMed